An observational study in Stroke, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-18.
Sponsored by Hospices Civils de Lyon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Stroke by Hospices Civils de Lyon — 13 open to participants now, 14 under way, none of them phase 3. Stroke · Hospices Civils de Lyon.
Among the 40 studies in Stroke by Hospices Civils de Lyon, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 30th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →13 of the 40 studies in Stroke by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18–85
Hospices Civils de Lyon · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 30–80
Hospices Civils de Lyon · Sites in France
Ages 18–100
Hospices Civils de Lyon · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 65 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 30 is below the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 50 across the 26 interventional studies, 348 across the 14 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
3 of the studies in Stroke by Hospices Civils de Lyon that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04197258Hospices Civils de LyonEvaluation of the Impact of an Individual Peer Support Intervention for Stroke Patients When Returning Home: a Mixed Methods Pilot Study | 2026-12-05 |
| NCT05874154Hospices Civils de LyonEvaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post-stroke Patients According to a Goal-centered Approach | 2027-03-02 |
| NCT06306144Hospices Civils de LyonEarly-phase Telecare Programs for Minor Stroke | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Stroke by Hospices Civils de Lyon, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. There are brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.
Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. The probability of stroke recurrence is high: about 25% the first year , and 30 to 40% in the 5 years following the stroke. Recurrent strokes are responsible for significant disability, institutionalization, major neurocognitive disorders, and death.
In order to reduce the risk of stroke recurrence, multiple secondary prevention strategies have demonstrated their effectiveness, such as the prescription of drugs (in particular statins and antithrombotics), the establishment of a balanced diet, the practice of an activity physical, or even tobacco addiction.
However, the effectiveness of these strategies is optimal if and only if patients adhere to them.
In addition, previous studies have focused on the brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.
In elderly patients, other obstacles could have been identified by specific studies, such as cognitive, sensory, functional disorders or even isolation.
Patients aged 65 and over, hospitalized for an ischemic stroke or a recurrence of ischemic stroke, being already treated with an antithrombotic treatment hospitalized at the Charpennes hospital with a plan to return home
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
elderly patients previously treated with an antithrombotic and admitted to hospital for an ischemic stroke
Other: Analysis of the verbatim from the transcription of the recorded interviews.
recorded semi-structured interviews between the patients and the pharmacist
Analysis of the verbatim from the transcription of the recorded interviews.
Describing the content of discussions, relating to antithrombotic treatment for secondary prevention, between elderly patients previously treated with antithrombotics and admitted to hospital for an ischemic stroke and a pharmacist
Time frame: one year
Analysis of verbatim statements from the transcription of recorded interviews on patients' representations and beliefs regarding antithrombotics
Exploring patients' representations and beliefs regarding antithrombotics before and after the onset of stroke or recurrence of stroke
Time frame: 15 to 60 minutes per patient
Analysis of verbatim statements from the transcription of recorded interviews on patients' medication adherence to antithrombotics
Explore patients' medication adherence to antithrombotics before the onset of stroke or recurrence of stroke
Time frame: 15 to 60 minutes per patient
Analysis of verbatim statements from the transcription of recorded interviews on the impact of the occurrence of stroke or recurrence of stroke on medication adherence
Explore the impact of stroke occurrence or stroke recurrence on patient medication adherence (including motivation, ambivalence, confidence in medication benefits)
Time frame: 15 to 60 minutes per patient
Analysis of verbatim statements from the transcription of recorded interviews on the obstacles and levers to medication adherence
Identify the barriers and levers to drug adherence with antithrombotics
Time frame: 15 to 60 minutes per patient
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2025; primary completion for Apr 2026, 12 months later.
Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 12 months is below that.
Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.